The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Regeneron Pharmaceuticals Inc

Nasdaq: REGN
Last

(U.S.) $509.70

Today's change-9.08 -1.75%
Updated September 3 3:55 PM EDT. Delayed by at least 15 minutes.
 

Regeneron Pharmaceuticals Inc

Nasdaq: REGN
Last

(U.S.) $509.70

Today's change-9.08 -1.75%
Updated September 3 3:55 PM EDT. Delayed by at least 15 minutes.

Regeneron Pharmaceuticals Inc down (U.S.)$9.08

Regeneron Pharmaceuticals Inc closed sharply lower Thursday, dropping (U.S.)$9.08 or 1.75% to (U.S.)$509.70. Shares have lost 5.26% over the last five days, but have gained 24.24% over the last year to date. This security has outperformed the S&P 500 by 43.21% during the last year.

Key company metrics

  • Open(U.S.) $523.45
  • Previous close(U.S.) $518.78
  • High(U.S.) $523.64
  • Low(U.S.) $506.83
  • Bid / Ask(U.S.) $509.49 / (U.S.) $510.11
  • YTD % change+24.24%
  • Volume522,595
  • Average volume (10-day)1,034,816
  • Average volume (1-month)866,677
  • Average volume (3-month)762,000
  • 52-week range(U.S.) $320.06 to (U.S.) $605.93
  • Beta0.74
  • Trailing P/E126.75×
  • P/E 1 year forward42.60×
  • Forward PEG1.89×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $4.02
Updated September 3 3:55 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+13.56%

Based on its net profit margin of 13.56%, Regeneron Pharmaceuticals Inc is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.39%Sector:HealthcareIndustry:Pharmaceuticals - Diversified
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2015Q1/2015Q4/2014Q3/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014
Revenue999870802726
Total other revenue--------
Total revenue999870802726
Gross profit910786743670
Total cost of revenue89845956
Total operating expense670587578543
Selling / general / administrative175159144150
Research & development390343352338
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)161230
Other operating expenses, total--------
Operating income329283225183
Interest income (expense), net non-operating-3-6-6-9
Gain (loss) on sale of assets--------
Other--------
Income before tax328277221176
Income after tax1957611080
Income tax, total13320111196
Net income1957611080
Total adjustments to net income--------
Net income before extra. items1957611080
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items1957611080
Inc. avail. to common incl. extra. items1957611080
Diluted net income1957611083
Dilution adjustment----03
Diluted weighted average shares115115114117
Diluted EPS excluding extraordinary itemsvalue per share1.690.660.970.70
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share1.770.671.070.70